Deletion of CD36 exhibits limited impact on normal hematopoiesis and the leukemia microenvironment

BACKGROUND: CD36 has been identified as a potential therapeutic target both in leukemic cells and in the tumor immune microenvironment. In acute myeloid leukemia (AML), we found that APOC2 acts with CD36 to promote leukemia growth by activating the LYN-ERK signaling. CD36 also plays a role in lipid...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Yiting, Pospiech, Mateusz, Ali, Atham, Chandwani, Ritu, Vergel, Mary, Onyemaechi, Sandra, Yaghmour, George, Lu, Rong, Alachkar, Houda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210361/
https://www.ncbi.nlm.nih.gov/pubmed/37226083
http://dx.doi.org/10.1186/s11658-023-00455-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210361/
https://www.ncbi.nlm.nih.gov/pubmed/37226083
http://dx.doi.org/10.1186/s11658-023-00455-8

Ejemplares similares